Weinreich DM, Sivapalasingam S, Norton T, et al. - Researchers tested two completely human, neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a combined cocktail (REGN-COV2) to decrease the risk of the emergence of treatment-resistant mutant virus, in this ongoing, double-blind, phase 1–3 trial including nonhospitalized patients suffering from coronavirus disease 2019. Randomization (1:1:1) of patients was done to receive placebo, 2.4 g of REGN-COV2, or 8.0 g of REGN-COV2 and participants were prospectively characterized at baseline for endogenous immune response against SARS-CoV-2 (serum antibody–positive or serum antibody–negative). Findings of this interim analysis revealed that a decrease in viral load was conferred by the REGN-COV2 antibody cocktail, and a greater impact was evident in patients whose immune response had not yet been started or who exhibited a high viral load at baseline. Similar safety outcomes were observed in the combined REGN-COV2 dose groups and the placebo group.